Dr. David Badesch, MD
Pulmonology (Pulmonary Disease Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 170
Licensed in Colorado since 1987, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Virginia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CO license 28171 (first issued 1987; active) -
Hypertension Specialist Physician
CO license 28171 (first issued 1987; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Medical Center of the Rockies Loveland, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
- Longs Peak Hospital Longmont, CO
- Parkview Medical Center, Inc Pueblo, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 170
- Services billed
- 397
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 121 | 77 |
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 86 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 60 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 35 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ambrisentan | 162 |
| Opsumit (macitentan) | 134 |
| Tadalafil | 123 |
| Uptravi (selexipag) | 89 |
| Sildenafil Citrate Other prescribers in Aurora, CO | 85 |
| Furosemide Other prescribers in Aurora, CO | 83 |
| Spironolactone Other prescribers in Aurora, CO | 76 |
| Potassium Chloride Other prescribers in Aurora, CO | 60 |
| Amlodipine Besylate Other prescribers in Aurora, CO | 45 |
| Xarelto (rivaroxaban) Other prescribers in Aurora, CO | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 48 payments worth $42,210 in total to this clinician.
| Merck Sharp & Dohme LLC | $42,210 |
|---|
| Consulting Fee | $25,533 |
|---|---|
| Travel and Lodging | $16,150 |
| Food and Beverage | $528 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $10,240 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $9,134 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $5,760 |
| Merck Sharp & Dohme LLC Mar 17, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,720 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $1,992 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,860 |
| Merck Sharp & Dohme LLC Oct 20, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,628 |
| Merck Sharp & Dohme LLC May 28, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC Jul 7, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC Jul 2, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
All 36 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 15, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionPayment made to Third Party Organization not to Physician. | $286 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $10,240 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $382 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Oct 20, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,628 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands Company’s descriptionProvided as part of a clinical research engagement. | $154 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $78.18 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $9,134 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $371 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $122 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $18.54 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $18.54 |
| Merck Sharp & Dohme LLC Sep 27, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $371 |
| Merck Sharp & Dohme LLC Sep 27, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands Company’s descriptionProvided as part of a clinical research engagement. | $151 |
| Merck Sharp & Dohme LLC Jul 28, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC Jul 7, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC Jul 2, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC May 28, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $5,760 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,860 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $1,992 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $371 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $357 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $173 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL Company’s descriptionProvided as part of a clinical research engagement. | $71.32 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $367 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $184 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $179 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL Company’s descriptionProvided as part of a clinical research engagement. | $92.66 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $63.05 |
| Merck Sharp & Dohme LLC Mar 27, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $398 |
| Merck Sharp & Dohme LLC Mar 17, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,720 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $465 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $538,568 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmo…
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Merck Sharp & Dohme LLC - An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept MK-7962 Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organizati…
Merck Sharp & Dohme LLC - An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
Merck Sharp & Dohme LLC - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate th…
Novartis Pharmaceuticals Corporation - A phase 1 randomized doubleblind placebocontrolled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of single escalating doses of PF07868489 in healthy adult participants and repeat do…
Pfizer Inc. - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186 - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.